Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, |
ADRs |
||||
| Identification code | NVO | |||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) |
Price(s) and volume(s) |
|||||
| Price(s) | Volume(s) | |||||
| DKK 865.68 | 24.862 ADRs | |||||
| d) | Aggregated information
|
24.862 ADRs DKK 21,522.51 |
||||
| e) | Date of the transaction | 2024-04-05 | ||||
| f) | Place of the transaction | New York Stock Exchange | ||||
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, |
ADRs |
||||
| Identification code | NVO | |||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) |
Price(s) and volume(s) |
|||||
| Price(s) | Volume(s) | |||||
| DKK 864.99 | 7.904 ADRs | |||||
| d) | Aggregated information
|
7.904 ADRs DKK 6,836.92 |
||||
| e) | Date of the transaction | 2024-04-05 | ||||
| f) | Place of the transaction | New York Stock Exchange | ||||
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.
Contact for further information:
| Media: | |
| Ambre James-Brown +45 3079 9289 [email protected] |
Liz Skrbkova (US) +1 609 917 0632 [email protected] |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 [email protected] |
Jacob Martin Wiborg Rode +45 3075 5956 [email protected] |
| David Heiberg Landsted +45 3077 6915 [email protected] |
Mark Joseph Root (US) +1 848 213 3219 [email protected] |
| Sina Meyer +45 3079 6656 [email protected] |
Frederik Taylor Pitter +45 3075 8259 [email protected] |
Company announcement No 30 / 2024
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
